Claims

1. Use of an anti-Adrenomedullin (ADM) antibody, anti-ADM fragment binding to adrenomedullin or anti-ADM non-Ig protein scaffold binding to adrenomedullin in the manufacture of a medicament for the prevention or reduction of organ dysfunction or the prevention of organ failure in a patient with an acute disease or an acute condition, wherein said antibody, antibody fragment or non-Ig scaffold binds to a region of at least 4 amino acids within the sequence of amino acids 1-42 of mature human ADM as set out in SEQ ID NO: 24, wherein said organ is kidney, liver, heart, lung or small intestine.

2. The use of claim 1, wherein said organ is a kidney or liver.

3. The use of claim 1, wherein said organ is a heart.

4. The use of any one of claims 1 to 3, wherein said antibody or fragment or scaffold binds to the N-terminal region of adrenomedullin comprising amino acids 1-21 as set out in SEQ ID NO: 23.

5. The use of any one of claims 1 to 4, wherein said antibody, antibody fragment or non-Ig scaffold is monospecific.

6. The use of any one of claims 1 to 5, wherein said antibody, or antibody fragment or non-Ig scaffold exhibits a binding affiinity to ADM of at least 10^{-7} M.

7. The use of any one of claims 1 to 6, wherein said antibody, antibody fragment or non-Ig scaffold is not ADM-binding-Protein-1 (complement factor H).

8. The use of any one of claims 1 to 7, wherein said antibody, antibody fragment or non-Ig scaffold recognizes and binds to the N-terminal end (aa1) of adrenomedullin.

9. The use of any one of claims 1 to 8, wherein said antibody, antibody fragment or non-Ig scaffold is an ADM stabilizing antibody or fragment or scaffold that enhances the half life

(t1/2 half retention time) of adrenomedullin in serum, blood, plasma at least 10 %, at least 50 %, more than 50 % or more than 100%.

10. The use of any one of claims 1 to 9, wherein said antibody, antibody fragment or non-Ig scaffold blocks the ADM bioactivity not more than 80 %, or not more than 50%.

11. The use of any one of claims 1 to 10, wherein said disease is selected from the group consisting of sepsis, diabetes, cancer, heart failure, and shock.

12. The use of any one of claims 1 to 11, wherein said disease is not SIRS, sepsis, or septic shock.

13. The use of any one of claims 1 to 12, wherein said antibody or antibody fragment is a human monoclonal antibody or antibody fragment that binds to ADM or an antibody fragment thereof wherein the heavy chain comprises the sequences

SEQ ID NO: 1
GYTFSRYW

SEQ ID NO: 2
ILPGSGST

SEQ ID NO: 3
TEGYEYDGFDY

and wherein the light chain comprises the sequences

SEQ ID NO:4
QSIVYSNGNTY

SEQ ID NO: 5
RVS

SEQ ID NO: 6

FQGSHIPYT.

14. The use of any one of claims 1 to 13, wherein said antibody, antibody fragment or non-Ig scaffold is a modulating antibody, antibody fragment or non-Ig scaffold that enhances the half life (tl/2 half retention time) of adrenomedullin in serum, blood, plasma at least 10 %, at least 50 %, more than 50 %, or more than 100% and that blocks the ADM bioactivity not more than 80 %, or not more than 50%.

15. The use of any one of claims 1 to 14, wherein said medicament is to be administered in combination with one or more vasopressors and/ or fluids administered intravenously.

16. The use of claim 15, wherein the one or more vasopressors comprises catecholamine.

17. The use of any one of claims 1 to 16, wherein said medicament is to be administered in combination with ADM binding protein and/or further active ingredients.

18. The use of any one of claims 1 to 17, wherein said medicament is to be administered intra-muscularly, intra-vascularly or systemically.

19. The use of claim 1, wherein said medicament is formulated as a solution or in a freeze-dried state.

20. The use of claim 19, wherein said solution is a ready-to-use solution.

21. The use of any one of claims 1, 19 to 20, wherein said medicament is formulated for intra-muscular or intra-vascular administration.

22. The use of any one of claims 1, 19 to 21, wherein said medicament is formulated for administration via infusion.

23. The use of any one of claims 1, 19 to 22, wherein said medicament is formulated for systemic administration.